Alirocumab Global Market Report 2026

Alirocumab is a fully human monoclonal antibody that blocks proprotein convertase subtilisin kexin type 9, a protein that regulates cholesterol levels, thereby improving the liver's ability to clear low-density lipoprotein cholesterol from the blood and effectively reducing overall cholesterol through targeted biological action. It is mainly prescribed for treating hypercholesterolemia and lowering cardiovascular risk, especially in patients who need additional cholesterol reduction beyond standard treatments or who cannot tolerate or respond adequately to conventional therapies.

The primary indications of alirocumab include familial hypercholesterolemia, atherosclerotic cardiovascular disease, secondary hyperlipidemia, and patients presenting high cardiovascular risk. Familial hypercholesterolemia refers to an inherited disorder marked by significantly elevated low-density lipoprotein cholesterol levels, thereby increasing the likelihood of premature cardiovascular complications. The administration routes include subcutaneous injection and self-administration, and it is utilized across diverse patient groups including geriatric, pediatric, and gender-specific populations. The treatment regimen encompasses both first-line and second-line therapies, and distribution occurs through hospitals, clinics, online pharmacies, retail pharmacies, and other distribution channels.

Tariffs are influencing the alirocumab market by raising costs and disrupting the international supply chain of biologic drug production, including monoclonal antibody manufacturing, cold chain distribution systems, and sourcing of raw materials. This particularly impacts subcutaneous injectable treatments supplied through hospitals, clinics, and specialty pharmacies, with Asia-Pacific and North America being key regions affected due to their dependence on cross-border pharmaceutical trade. Increased import duties on biologics and related bioprocessing inputs have resulted in higher treatment costs and slower patient access in certain markets. Nevertheless, tariffs are also promoting the localization of biologics production, enhancing regional manufacturing capabilities, and supporting stronger long-term supply chain resilience.

The alirocumab market research report is one of a series of new reports from The Business Research Company that provides alirocumab market statistics, including alirocumab industry global market size, regional shares, competitors with a alirocumab market share, detailed alirocumab market segments, market trends and opportunities, and any further data you may need to thrive in the alirocumab industry. This alirocumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alirocumab market size has grown rapidly in recent years. It will grow from $2.1 billion in 2025 to $2.32 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to rising ldl cholesterol prevalence, increasing cardiovascular disease burden, statin therapy limitations, early biologics adoption in lipid management, clinical guideline advancements in hypercholesterolemia.

The alirocumab market size is expected to see rapid growth in the next few years. It will grow to $3.48 billion by 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to aging global population growth, expansion of pcsk9 inhibitor pipeline, increasing reimbursement coverage for biologics, growth in home-based self-administration therapies, expansion of cardiovascular preventive care programs. Major trends in the forecast period include increasing adoption of pcsk9 inhibitor therapies, rising prevalence of statin intolerance patients, expansion of cardiovascular risk screening programs, growth in monoclonal antibody-based lipid lowering therapies, rising demand for combination lipid lowering regimens.

The growing incidence of cardiovascular diseases is anticipated to propel the expansion of the alirocumab market in the coming years. Cardiovascular diseases represent a cluster of disorders impacting the heart and blood vessels, encompassing conditions such as coronary artery disease, cerebrovascular disease, and heart failure, which together hinder the effective circulation of blood and oxygen throughout the body. A major contributor to the rising incidence of cardiovascular diseases is the widespread prevalence of sedentary lifestyles, as limited physical activity leads to metabolic imbalance, encourages excessive fat accumulation, and speeds up the emergence of risk factors such as hypertension and dyslipidemia, thereby substantially increasing the probability of cardiovascular complications over time. Alirocumab works by reducing low-density lipoprotein cholesterol levels through the inhibition of proprotein convertase subtilisin/kexin type 9, thereby assisting in lowering cardiovascular risk and managing disease progression in populations increasingly impacted by these conditions. For example, in June 2024, according to data released by the American Heart Association Inc., a US-based non-profit organization, cardiovascular disease prevalence in the United States is expected to increase from around 50% of adults currently to 61% by 2050. Therefore, the growing incidence of cardiovascular diseases is driving the expansion of the alirocumab market.

Leading companies operating in the alirocumab market are focusing on developing innovative products, such as expanded indication biologics to broaden patient eligibility and enhance early-stage disease management. An expanded indication biologic is a therapeutic agent that receives regulatory approval for use in additional patient populations or disease conditions beyond its original indication. For example, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, announced U. S. Food and Drug Administration approval for Praluent. This development extends the use of alirocumab to pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia, enabling earlier intervention in genetically predisposed individuals. The approval strengthens preventive cardiovascular care by improving low-density lipoprotein cholesterol management and expanding the therapy's clinical and commercial scope.

The increasing adoption of personalized medicine strategies is anticipated to fuel the growth of the alirocumab market in the future due to the rising need for targeted therapies that enable accurate treatment and improved cardiovascular risk management outcomes. Personalized medicine refers to a healthcare approach that customizes treatment plans based on individual patient characteristics, including genetic makeup, biomarker information, lifestyle factors, and disease-specific attributes, with the aim of enhancing treatment effectiveness and reducing adverse effects. A key driver behind the growing adoption of personalized medicine is the expanding integration of genomic data into clinical practice, as advances in genetic profiling allow healthcare providers to more accurately identify disease risks and treatment responses, thereby enabling more precise and effective therapeutic decisions. Alirocumab contributes to personalized medicine by providing a targeted lipid-lowering treatment particularly useful for patients with genetic lipid disorders or those who do not respond adequately to standard therapies, thereby improving individualized cardiovascular risk management. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, more than one-third of all new drug approvals by the U. S. Food and Drug Administration have consistently been personalized therapies for four consecutive years through 2023, with 2023 approvals including 16 rare disease treatments (compared to six in 2022), along with seven oncology drugs and three therapies for other conditions. Therefore, the increasing adoption of personalized medicine strategies is driving the growth of the alirocumab market.

Major companies operating in the alirocumab market are Sanofi S. A., Regeneron Pharmaceuticals Inc.

North America was the dominating region in the alirocumab market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the alirocumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the alirocumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alirocumab market consists of sales of anticoagulants, blood-thinning medications, anti-hypertensive drugs, and high-dose ophthalmology biologics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alirocumab Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses alirocumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alirocumab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The alirocumab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Indication: Familial Hypercholesterolemia; Atherosclerotic Cardiovascular Disease; Secondary Hyperlipidemia; High Cardiovascular Risk Patients
• 2) By Administration Route: Subcutaneous Injection; Self-Administration
• 3) By Patient Demographics: Geriatric; Pediatric; Gender-Based
• 4) By Treatment Line: First-Line Treatment; Second-Line Treatment
• 5) By Distribution Channel: Hospitals; Clinics; Online Pharmacies; Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Familial Hypercholesterolemia: Heterozygous Familial Hypercholesterolemia; Homozygous Familial Hypercholesterolemia
• 2) By Atherosclerotic Cardiovascular Disease: Coronary Artery Disease; Peripheral Artery Disease; Cerebrovascular Disease
• 3) By Secondary Hyperlipidemia: Diabetes Induced Hyperlipidemia; Obesity Related Hyperlipidemia; Hypothyroidism Induced Hyperlipidemia
• 4) By High Cardiovascular Risk Patients: Hypertension Patients; Smokers At Risk; Elderly Population At Risk; Metabolic Syndrome Patients
• Companies Mentioned: Sanofi S.A.; Regeneron Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.